Pharmaceuticals, Biotechnology and Life Sciences
LOUGHBOROUGH, England–(BUSINESS WIRE)–Nemaura Pharma Limited, a UK based Biopharmaceutical company specializing in transdermal and injectable drug delivery systems today announced…
Ipsen got approval for Dysport, the first and only FDA-approved botulinum toxin for treatment of both pediatric upper and lower limb spasticity, as the pivotal Phase 3 study showed Dysport improved spasticity symptoms in children aged two to 17 experiencing upper limb spasticity, as measured by the primary efficacy endpoint of Modified Ashworth Scale at elbow or wrist flexors at Week 6.
Nevome Biotherapeutics has started testing its ST266 when delivered intranasally in a Phase 1 open label clinical trial, in patients diagnosed with intraocular hypertension who have not yet developed optic nerve damage, with topline results expected by end of the second quarter of 2020.
Curevo Vaccine’s interim trial results showed a promising safety and tolerability profile of the Shingles vaccine in 90 healthy adults ≥18 to <50 were presented in an oral presentation at the 44th annual International Herpesvirus Workshop in Knoxville, Tennessee.
Phase-1b/2 Clinical Data for Aura’s Lead Asset, AU-011, to be Highlighted at the Meeting and at Other Related Events CAMBRIDGE,…
cTAP has published a comprehensive analysis of the North Star Ambulatory Assessment (NSAA), a newly adopted primary outcome measure in clinical trials of patients with Duchenne Muscular Dystrophy.
Takeda’s presentation has shown TAK-925 was well tolerated in patients with narcolepsy type 1 and increased wakefulness compared to placebo.
LOS ANGELES–(BUSINESS WIRE)–Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President…
– Presentation to be webcast on www.exelixis.com – ALAMEDA, Calif.–(BUSINESS WIRE)–Exelixis, Inc. (Nasdaq: EXEL) today announced that members of Exelixis…
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Dicerna™ Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi)…